ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2204 • ACR Convergence 2022

    Interosseous Tendon Inflammation in the Hands: A Novel Feature of Developing Rheumatoid Arthritis? Results from a Large MRI Study in Clinically Suspect Arthralgia

    Bastiaan van Dijk1, Hanna van Steenbergen1, Monique Reijnierse2, Sarah J.H. Khidir2, Lambertus Wisse1, Marco deRuiter1 and Annette van der Helm-van Mil3, 1Leiden University Medical Centre (LUMC), Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Inflammation around the tendons of hand interosseous muscles (interosseous tendon inflammation; ITI) on MRI was recently reported for the first time in rheumatoid arthritis…
  • Abstract Number: 2171 • ACR Convergence 2022

    Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous Systemic Sclerosis

    Ranjitha Karanth1, Giuseppina Abignano2, Vishal Kakkar1, Rebecca Ross1, Chris Denton3 and Francesco Del Galdo4, 1University of Leeds, Leeds, United Kingdom, 2Istituto Reumatologico Lucano (IReL), Azienda Ospedaliera Regionale San Carlo, Potenza, Italy, 3University College London, London, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Type-I Interferon pathway activation has been associated with severity and progression of diffuse cutaneous SSc (dcSSc). The role of type-I Interferons (IFNs) in limited…
  • Abstract Number: 2223 • ACR Convergence 2022

    Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus

    Julius Lindblom1, Daniel Toro-Domínguez2, Elena Carnero-Montoro2, Maria Orietta Borghi3, Jessica Castillo4, Ellen Iacobaeus1, Yvonne Enman5, Chandra Mohan4, Marta Alarcon-Riquelme2, Guillermo Barturen2 and Ioannis Parodis1, 1Karolinska Institutet, Stockholm, Sweden, 2Center for Genomics and Oncological Research (GENYO), Granada, Spain, 3Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, 4University of Houston, Houston, TX, 5Karolinska Institutet, Sundbyberg, Sweden

    Background/Purpose: Involvement of the nervous system is a common but poorly understood manifestation of SLE, termed NPSLE. Although studies have reported varying prevalence estimates (Unterman…
  • Abstract Number: 2225 • ACR Convergence 2022

    Physical Inactivity Is Associated with Increased Expression of T Cell Inflammatory Genes in Systemic Lupus

    Sarah Patterson1, Sebastian Cruz Gonzalez2, Alexandra Tsitsiklis2, Cristina Lanata3, Lenka Maliskova4, Chun Ye1, Zachary Cutts4, Jinoos Yazdany5, Maria Dall'Era6, Lindsey Criswell7, Charles Langelier2, Patricia Katz5 and Marina Sirota8, 1University of California, San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA, 3NIH, Washington, DC, 4University of California, San Francisco, San Francisco, 5UCSF, San Rafael, CA, 6University of California, Division of Rheumatology, San Francisco, CA, 7National Human Genome Research Institute, NIH, Bethesda, MD, 8UCSF, SF

    Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…
  • Abstract Number: 2210 • ACR Convergence 2022

    Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study

    Athimalaipet Ramanan1, Pierre Quartier Dit Maire2, Nami Okamoto3, Gabriella Meszaros4, Joana Araujo4, Zhongkai Wang4, Ran Liao4, Brenda Crowe4, Xin Zhang4, Rodney Decker4, Stuart Keller4, Hermine Brunner5 and Nicola Ruperto6, 1Bristol Royal Hospital for Children, Bristol, United Kingdom, 2Necker hospital, Paris Cedex 15, France, 3Osaka Medical College, Takatsuki-city, Japan, 4Eli Lilly and Company, Indianapolis, IN, 5Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, 6IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy

    Background/Purpose: Baricitinib is a JAK1/2 selective inhibitor approved for the treatment of rheumatoid arthritis. Juvenile idiopathic arthritis (JIA) is a group of diseases characterized by…
  • Abstract Number: 2216 • ACR Convergence 2022

    JAK Inhibitors and Risk of Cancer

    Amandine Gouverneur1, Jérôme Avouac2, Clément Prati3, Jean-Luc Cracowski4, Thierry schaeverbeke5, Antoine Pariente1 and Marie-Elise Truchetet5, 1Université de Bordeaux, Bordeaux, France, 2University of Paris, Paris, France, 3Service de rhumatologie, CHU de Besançon, Besançon, France, 4Université de Grenoble, Grenoble, France, 5CHU de Bordeaux, Bordeaux, France

    Background/Purpose: Recent concerns have been raised about potential increase of cancer risk under JAK inhibitors (JAKi) especially tofacitinib. Discrepant findings have been given by randomized…
  • Abstract Number: 2222 • ACR Convergence 2022

    Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile

    Gregg Silverman1, Macintosh Cornwell1, Peter Izmirly1, Mala Masson1, Jill Buyon1, Doua Azzouz2 and Kelly Ruggles1, 1NYU Grossman School of Medicine, New York, NY, 2NYU Gross School of Medicine, New York, NY

    Background/Purpose: SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common.…
  • Abstract Number: 2218 • ACR Convergence 2022

    Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis

    Namrata Singh1, Laura Gold2, Katherine Wysham3, James Andrews2, Pankti Reid4, Una Makris5, Bryant England6, Jiha Lee7, Michael George8, Joshua Baker9, Jeffrey Jarvik2, Patrick Heagerty2 and Siddharth Singh10, 1University of Washington, Bellevue, WA, 2University of Washington, Seattle, WA, 3VA Puget Sound/University of Washington, Seattle, WA, 4University of Chicago Medical Center, Chicago, IL, 5UT Southwestern Medical Center and Dallas VA, Dallas, TX, 6University of Nebraska Medical Center, Omaha, NE, 7University of Michigan, Ann Arbor, MI, 8University of Pennsylvania, Philadelphia, PA, 9University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 10University of California San Diego, San Diego

    Background/Purpose: Recently, it has been recognized that frailty and pre-frailty are common in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased…
  • Abstract Number: 2166 • ACR Convergence 2022

    Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments

    Eric Schwender1, Dylan Hansen2, Wendy Stevens2, Laura Ross3, Nava Ferdowsi2, Susanna Proudman4, Jenny Walker5, Jo Sahhar6, Gene-Siew Ngian7, Lauren Host8, Gabor Major9, Mandana Nikpour10 and Kathleen Morrisroe2, 1Royal College of Surgeons, Dublin, Ireland, 2St Vincent's Hospital Melbourne, Melbourne, Australia, 3The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, 4Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, 5Royal Adelaide Hospital, Adelaide, Australia, 6Monash Health, Melbourne, Australia, 7Melbourne Health, Northcote, Australia, 8Fiona Stanley Hospital, London, United Kingdom, 9Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, 10The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: To characterise a cohort of Australian scleroderma patients with inflammatory arthritis including patient characteristics, autoantibody profile, therapy and impact on function and quality of…
  • Abstract Number: 2161 • ACR Convergence 2022

    Alterations of Nutritional Status of Scleroderma Patients and Associations with Disease-specific Features

    Sabína Oreská1, Hana Storkanova1, Maja Spiritovic2, Barbora Hermankova2, Michal Vrablík3, Karel Pavelka4, Jiří Vencovský5, Ladislav Šenolt5, Radim Becvar1 and Michal Tomcik1, 1Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, 33rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and organ involvement and chronic disease course. In particular, involvement of the gastrointestinal tract and systemic inflammation…
  • Abstract Number: 2208 • ACR Convergence 2022

    Diagnostic Performance of Hip Ultrasound in Calcium Pyrophosphate Deposition Disease

    Carina Soto-Fajardo1, Fabian Carranza-Enriquez2, Sinthia Solorzano Flores2, Abish Angeles2, Paola Flores2, Raul Pichardo-Bahena2, Luis Javier Jara Quezada2, Angélica Peña Ayala2, Victor-Manuel Ilizaliturri-Sanchez2, Georgios Filippou3 and Carlos Pineda2, 1Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, 2Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, 3Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy

    Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a chronic and potentially incapacitating disease. The reference standard for its diagnosis is the identification of calcium pyrophosphate…
  • Abstract Number: 2164 • ACR Convergence 2022

    Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease

    Nikolay Markov1, Karolina Senkow1, Anthony Esposito2, Jonathan Puchalski3, Mridu Gulati3, Erica Herzog3, Danielle Antin-Ozerkis4, Mary Carns5, Alyssa Williams6, Nic Page6, Alexander Misharin1 and Monique Hinchcliff7, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Brigham and Women's Hospital, Department of Medicine, Boston, MA, 3Yale School of Medicine, New Haven, CT, 4Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Yale University, New Haven, CT, 7Yale School of Medicine, Westport, CT

    Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc). Previously, profibrotic monocyte-derived alveolar macrophages (MoAM) expressing (SPP1,…
  • Abstract Number: 1782 • ACR Convergence 2022

    Sociocultural and Moral Factors Influencing the Decision to Vaccinate Among Rheumatic Patients: A Qualitative Study

    Tirsa Colmenares-Roa1, Amaranta ManriquedeLara2, Virginia Pascual Ramos3, JOSE FRANCISCO MOCTEZUMA RIOS4, Irazu Contreras-Ibañez5, Everardo Alvarez-Hernandez6, Guillermo Guaracha Basañez7, Graciela Meza-LópezyOlguin4 and Ingris Pelaez-Ballestas1, 1Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México, Mexico, 2Hospital General de México "Dr. Eduardo Liceaga,", Ciudad de México, Mexico, 3Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, 4HOSPITAL GENERAL DE MEXICO "Dr. Eduardo Liceaga", Ciudad de México, Mexico, 5Instituto Nacional de Nutricion Salvador Zubirán, Ciudad de México, Mexico, 6Hospital General de Mexico "Dr.Eduardo Liceaga", Ciudad de México, Mexico, 7Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico

    Background/Purpose: Vaccination is a process that involves individual, social and moral aspects, beyond public governance of vaccines or vaccination as a public health concern. The…
  • Abstract Number: 1785 • ACR Convergence 2022

    PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort

    Susan Bartlett1, orit schieir2, Marie-France Valois2, Janet Pope3, Louis Bessette4, Gilles Boire5, Carol Hitchon6, Edward Keystone7, Carter Thorne8, Diane Tin9, Glen Hazlewood10 and Vivian Bykerk11, 1McGill University, Montreal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3University of Western Ontario, London, ON, Canada, 4Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8Southlake Regional Health Centre, Newmarket, ON, Canada, 9The Arthritis Program Research Group, Newmarket, ON, Canada, 10University of Calgary, Calgary, AB, Canada, 11Hospital for Special Surgery, New York, NY

    Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…
  • Abstract Number: 2167 • ACR Convergence 2022

    Autoantibodies in Patients with Early Systemic Sclerosis in the Collaborative National Quality and Efficacy Registry

    Alyssa Bosso1, Shervin Assassi2, Tracy Frech3, Jessica Gordon4, Elana Bernstein5, Carrie Richardson6, Nora Sandorfi7, Laura Hummers8, Ami Shah9, Dinesh Khanna10, Lorinda Chung11, Flavia Castelino12, Faye Hant13, Victoria Shanmugam14, John VanBuren15, Angela Larkin16, Luke Evnin17 and Virginia Steen18, 1Medstar Georgetown University Hospital, Washington, DC, 2McGovern Medical School, University of Texas, Houston, TX, 3Vanderbilt University Medical Center, Nashville, TN, 4Hospital for Special Surgery, New York, NY, 5Columbia University, New York, NY, 6Northwestern University, Riverside, IL, 7University of Pennsylvania, Philadelphia, PA, 8Johns Hopkins Univerisity, Baltimore, MD, 9Johns Hopkins Rheumatology, Baltimore, MD, 10Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 11Stanford University, Stanford, CA, 12Massachusetts General Hospital, Boston, MA, 13Medical University of South Carolina, Charleston, SC, 14George Washington University, Great Falls, VA, 15University of Utah, Salt Lake City, UT, 16University of Utah Health, Salt Lake City, UT, 17Scleroderma Research Foundation, Brisbane, CA, 18Georgetown University School of Medicine, Washington, DC

    Background/Purpose: We sought to describe the autoantibody profile of SSc patients with early disease and examine the clinical, laboratory and prognostic features associated with these…
  • « Previous Page
  • 1
  • …
  • 480
  • 481
  • 482
  • 483
  • 484
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology